IP Group
IPO
Performance
About IP Group
IP Group plc is a leading UK-based investment firm that specializes in early-stage funding and development of innovative businesses in sectors such as deeptech, life sciences, and cleantech. With a commitment to accelerating scientific progress for a better future, the company backs transformative companies and technologies emerging from universities and research institutions, notably through its partnership with Parkwalk, the UK's largest growth EIS fund manager. IP Group has a strong track record, having supported notable companies like Oxford Nanopore Technologies and First Light Fusion, and is publicly traded on the London Stock Exchange.
Recent News
SLAMCORE SECURES $14M, BACKED BY INVESTORS INCLUDING ROCKWELL AUTOMATION, TO SCALE VISUAL AI ACROSS INTRALOGISTICS
Barocal Raises $10M To Scale Solid-State Cooling Technology
Alesi Surgical Secures £7m to Tackle Hazardous Surgical Smoke in Operating Theatres, Led by IW Capital
Storm Therapeutics Secures $56M to Advance Cancer Drugs
Mantle8 Secures €31 Million Series A to Commercialize Natural Hydrogen
Alesi Surgical Raises £7M to Clear the Air in Operating Theatres with Next-Gen Smoke Management Tech
Storm Therapeutics Secures $56 Million Series C to Push METTL3 Cancer Drug Into Phase 2
STORM Therapeutics Raises €47.5 Million Series C to Harness the Power of RNA Modification to Treat Cancer
Cambridge Biotech STORM Therapeutics Raises $56M
Recent Deals
Alesi Surgical Raises £7m ($8.8M) in Growth-Stage Funding Led by IW Capital
Mission Therapeutics Raises $13.3M From Existing Strategic Investors
Slamcore Secures $14M Funding Round Backed by Investors Including Rockwell Automation's ROKStar Ventures
STORM Therapeutics Raises $56M Series C to Advance RNA-Modification Cancer Therapy